New medical treatments for endometriosis

David L. Olive, Olive DL, Lindheim SR, Steven R Lindheim, Elizabeth A. Pritts, Pritts EA
Best practice & research. Clinical obstetrics & gynaecology · 2004 · vol. 18(2) , pp. 319–328 · doi:10.1016/j.bpobgyn.2004.03.005 · PMID:15157645 · W2023676059
review OA: closed CC0 ⤵ 68 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This paper reviews current and emerging medical treatments for endometriosis, discussing their mechanisms of action, efficacy, and side effect profiles.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The medical treatment of endometriosis has long centered upon producing a hypoestrogenic environment by producing pituitary suppression or a progestin-dominant environment. However, as more is uncovered regarding the pathogenesis and pathophysiology of this disease, more targeted therapies can be developed. Current research has focused upon medications designed to attack specific aspects of the development and maintenance of endometriosis. These include progesterone receptor modulators, gonadotropin releasing hormone (GnRH) antagonists, aromatase inhibitors, tumor necrosis factor alpha (TNF-alpha) inhibitors, angiogenesis inhibitors, matrix metalloproteinase inhibitors, pentoxifylline (and other general immune modulators), and estrogen receptor beta agonists. It is hoped that this new wave of medications will improve the response to medical therapy for this disorder.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Angiogenesis Inhibitors Angiogenesis Inhibitors Aromatase Inhibitors Aromatase Inhibitors Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Hormone Antagonists Hormone Antagonists Humans Immunologic Factors Immunologic Factors Matrix Metalloproteinase Inhibitors Mifepristone Mifepristone Receptors, Progesterone Receptors, Progesterone Tumor Necrosis Factor-alpha

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (32)

Cited by (50)

Source provenance

europepmc
last seen: 2026-07-30T06:25:42.655704+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:32.173627+00:00
License: CC0 · commercial use OK